Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1

Conditions

Mesothelioma, Malignant 1Lymphoma 1Colonic Neoplasms 1

Interventions

Pemetrexed 7Cisplatin 7Cyclophosphamide 5pembrolizumab 4fludarabine 4Platinum 3Drug Therapy 3aldesleukin 2Nivolumab 2Ipilimumab 2Interleukin-2 21,2-diaminocyclohexaneplatinum II citrate 2vatalanib 1spartalizumab 1regorafenib 1napabucasin 1methoxyamine 1fludarabine phosphate 1enzalutamide 1cediranib 1avelumab 1atezolizumab 1anetumab ravtansine 1Vorinostat 1Thiostrepton 1Tetrahydrouridine 1Radiosurgery 1Megestrol Acetate 1Levoleucovorin 1Leucovorin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Mesothelioma, Malignant × methoxyamine × Clear all
NCT02535312 2026-04-17

Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
30 enrolled 15 charts
Other solid neoplasmThoracic

Mesothelioma, Malignant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡